Nan Li is a venture capital investor at Dimension who built his career at the intersection of computer science and life sciences, positioning himself early around the convergence of computation and biology before it became mainstream. He focuses on partnering with technical founding teams developing platforms that generate proprietary biological datasets rather than generic AI models, emphasizing that differentiated data and infrastructure are the true advantages in computational drug discovery. Nan Li is a venture capital investor at Dimension who built his career at the intersection of computer science and life sciences, positioning himself early around the convergence of computation and biology before it became mainstream. He focuses on partnering with technical founding teams developing platforms that generate proprietary biological datasets rather than generic AI models, emphasizing that differentiated data and infrastructure are the true advantages in computational drug discovery.